GlassScriptPhysician profile
Donna Marie Howard
NPI 1265478978
$6,745.07
in general payments reported to CMS, 2019-2025
28 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,588 · 2022: $793 · 2023: $1,704 · 2024: $1,184 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,016 · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,015.98 |
| Education | $348.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $904.65 | 2021-2025 | |
| Pfizer INC. | $787.70 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $655.18 | 2021-2025 | Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $609.92 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $483.94 | 2021 | |
| Lilly USA, LLC | $381.45 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $348.87 | 2023-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $323.62 | 2022-2024 | Tremfya |
| Chugai Pharmaceutical Co., LTD. | $300.00 | 2021 | |
| Amgen INC. | $289.14 | 2024-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $286.68 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $277.61 | 2021-2024 | |
| Almirall LLC | $139.59 | 2021-2025 | Seysara, Klisyri |
| Incyte Corporation | $132.44 | 2021-2023 | Opzelura |
| Galderma Laboratories, L.P. | $130.49 | 2021-2025 | Nemluvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $113.25 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $90.82 | 2023-2024 | Zoryve |
| Biofrontera INC. | $89.17 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $74.06 | 2021-2023 | Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.46 | 2021-2023 | Siliq |
| Medimetriks Pharmaceuticals, INC. | $63.80 | 2022-2025 | Neo-Synalar |
| E.R. Squibb & Sons, L.L.C. | $49.40 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $26.84 | 2023 | Vtama |
| Organon LLC | $26.57 | 2025 | Vtama |
| Nabriva Therapeutics, Plc | $24.74 | 2021-2022 | |
| Merz North America, INC. | $24.23 | 2024 | |
| Dermira, INC. | $22.09 | 2021 | |
| Verrica Pharmaceuticals INC. | $20.36 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.